We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases
Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.
Building a great company with a focus on science, innovation, collaboration and entrepreneurship
Our revolutionary technology provides the foundation for building a sustainable innovation engine and a place to foster entrepreneurship across all fronts. We’re always looking for talented, experienced and passionate individuals to join us. We have our headquarters in Zug, Switzerland, our R&D operations in Cambridge, Massachusetts, USA and additional business operations in San Francisco, California. Please visit the careers page for more information.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.